Jie Tian

Dr. Jie Tian received his PhD degree (with honors) in artificial intelligence from Chinese Academy of Sciences in 1993. Since 1997, he has been a professor at  Chinese Academy of Sciences. Dr. Tian has been elected as the Fellow of AAAS,ISMRM, AIMBE,  IEEE, OSA, SPIE, and IAPR. He serves as the editorial board member of European Journal of Nuclear Medicine and Molecular Imaging, European Radiology, IEEE Transactions on Biomedical Engineering, IEEE Journal of Biomedical and Health Informatics, and Photoacoustics. He also serves as an advisory board member for Physics in Medicine & Biology. Dr. Tian has more than 100 granted patents in China and six patents in the United States. He is the author of over 300 peer-reviewed journal articles, including publication in Journal of Clinical Oncology,Nature biomedical engineering, Nature Communications, Gastroenterology, PNAS, Clinical Cancer Research, Radiology, IEEE TMI, TBE,JBO and many other journals, and these articles received about over 35,000 Google Scholar citations（H-index 93）. He is the editor of five academic books in the field of medical imaging, and his book, Molecular Imaging Fundamentals and Applications, is sold online for over 68,000 times.  He is one of the founders of Chinese Society for Molecular Imaging (CSMI), and was elected as the first president of CSMI (2010-2017).Dr. Tian is recognized as a pioneer and a leader in China in the field of molecular imaging. In the last two decades, he has developed a series of new optical imaging models and reconstruction algorithms for in vivo optical tomographic imaging, including bioluminescence tomography, fluorescence molecular tomography, and Cerenkov luminescence tomography. He has developed various types of molecular imaging instrumentations, such as optical-CT-MRI-PET hybrid multimodality imaging system, optical projection tomography system, endoscopic Cerenkov luminescence imaging system, photoacoustic and fluorescence hybrid imaging system, etc. He has developed new artificial intelligence strategies for medical imaging big data analysis in the field of Radiomics, and played a major role in establishing a standardized Radiomics database with more than 100,000 cancer patients data collected from over 60 hospitals all over China.
Currently, he is translating novel intraoperative fluorescence imaging technologies, including new optical molecular imaging systems and molecular probes, for navigating liver cancer, lung cancer, and breast cancer surgeries in multi-center clinical trials in China. He has received $60 million from the National Natural Science Foundation of China (NSFC) and Chinese Ministry of Science and Technology (CMST). He has received numerous awards, including five national top awards for his outstanding work in medical imaging.